Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $9.7050 (2.75%) ($9.7050 - $9.7150) on Mon. Apr. 4, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.35% (three month average) | RSI | 62 | Latest Price | $9.7050(2.75%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD advances 0.7% a day on average for past five trading days. | Weekly Trend | FOLD advances 0.2% a week on average for past two weeks. | Market Behavior | Growth stock rally for large cap. Growth stock rally for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(63%) IWO(50%) IWC(47%) IWM(47%) XBI(44%) | Factors Impacting FOLD price | FOLD will decline at least -2.175% in a week (0% probabilities). VIXM(-26%) VXX(-12%) UUP(-10%) UNG(-9%) EDOC(-4%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -2.175% (StdDev 4.35%) | Hourly BBV | 0.7 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $9.62(0.88%) | 10 Day Moving Average | $9.53(1.84%) | 20 Day Moving Average | $9.4(3.24%) | To recent high | -22.1% | To recent low | 23.1% | Market Cap | $2.506b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |